Sidney Kimmel – Jefferson joins Driver network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Sidney Kimmel Cancer Center – Jefferson Health announced a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which has launched in the United States and China.

Driver’s platform enables any patient, anywhere in the world, to access treatment options across an unprecedented network of cancer centers without leaving home.

NCI and the Chinese National Cancer Center are the founding members of Driver’s global network. To date, more than thirty leading cancer centers in addition to SKCC comprise Driver’s network, including the Cleveland Clinic; Mayo Clinic; Massachusetts General Hospital; University of California, San Francisco; University of California, Los Angeles; Duke University; University of North Carolina; and Emory.

In order to provide patients with extensive cancer treatment options and information, Driver processes medical records and tumor data, then offers current evidence-based treatment guidelines as well as information on clinical trials for which a patient is potentially eligible that are being offered at any of the cancer centers in Driver’s network.

Driver’s lead investor is Horizons Ventures, with whom Driver has partnered from its inception to build its platform in China in parallel to the United States.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login